Jennifer Doudna

Nobel Laureate, Professor at UC Berkeley, President of the Innovative Genomics Institute · Person

Mentions

Episodes

Claims

Jennifer Doudna — Nobel Laureate, Professor at UC Berkeley, President of the Innovative Genomics Institute. Tracked across 18 mentions in podcasts and expert conversations analyzed by Sonic.

What Jennifer Doudna has said

Jennifer Doudna does not believe AI chatbots are currently capable of genuine innovation or generating novel scientific ideas.

neutral·Jennifer Doudna

In 2014, Jennifer Doudna and Jonathan Wiseman co-founded the nonprofit Innovative Genomics Institute.

neutral·Ruth

Jennifer Doudna was awarded the 2020 Nobel Prize in Chemistry for her role in developing the CRISPR-Cas9 genome engineering technology.

neutral·Ruth

Jennifer Doudna does not believe AI chatbots are currently capable of genuine innovation or generating novel scientific ideas.

Expert perspectiveJennifer DoudnaJun 25

In 2014, Jennifer Doudna and Jonathan Wiseman co-founded the nonprofit Innovative Genomics Institute.

Official sourceRuthMay 4

Jennifer Doudna was awarded the 2020 Nobel Prize in Chemistry for her role in developing the CRISPR-Cas9 genome engineering technology.

Official sourceRuthMay 4

CRISPR technology is being used in clinical trials to correct a protein-aggregating liver disease by editing genes in the liver.

Expert perspectiveJennifer DoudnaMay 4

CRISPR technology is being used in clinical trials to correct the mutations responsible for sickle cell disease.

Expert perspectiveJennifer DoudnaMay 4

CRISPR technology is being applied in cancer immunotherapy to engineer the immune system to more effectively target and attack certain types of cancer cells.

Expert perspectiveJennifer DoudnaMay 4

The Innovative Genomics Institute is researching new delivery strategies for CRISPR editors into bone marrow that would eliminate the need for a bone marrow transplant, thereby reducing the cost and h...

Expert perspectiveJennifer DoudnaMay 4

The Innovative Genomics Institute, in a three-way partnership with the University of California, Berkeley, UCSF, and UCLA, is conducting an FDA-approved Phase 1 clinical trial for a CRISPR-based thera...

Official sourceJennifer DoudnaMay 4

CRISPR is an adaptive immune system in bacteria that uses RNA molecules, transcribed from viral DNA, to find and destroy the genetic material of invading viruses.

Expert perspectiveJennifer DoudnaMay 4

A significant challenge in the field of genome editing is ensuring the precision of CRISPR, specifically the ability to precisely dictate the exact change made to the DNA.

Expert perspectiveJennifer DoudnaMay 4

The CRISPR-Cas9 protein cuts DNA molecules using an RNA guide.

Expert perspectiveJennifer DoudnaMay 4

A known risk of CRISPR gene editing is the potential for 'off-target' edits, where the technology makes changes at unintended locations in the genome.

Expert perspectiveJennifer DoudnaMay 4

In early 2015, the Innovative Genomics Institute convened a meeting of US scientists and leaders from the Asilomar meeting to discuss the ethics of CRISPR applications.

Expert perspectiveJennifer DoudnaMay 4

The Innovative Genomics Institute is the only nonprofit organization currently running a clinical trial for a CRISPR-based sickle cell therapy.

Official sourceJennifer DoudnaMay 4

Jennifer Doudna predicts that CRISPR technology will be transformative in agriculture by enabling genetic changes in plants and their supporting microorganisms.

Expert perspectiveJennifer DoudnaMay 4

At the end of 2018, an announcement was made that CRISPR had been used to edit human embryos, which resulted in a pregnancy and the birth of twins with edited genes.

Expert perspectiveJennifer DoudnaMay 4

The World Health Organization and national academies in multiple countries are investigating the potential of CRISPR technology and appropriate ways to regulate it.

Expert perspectiveJennifer DoudnaMay 4

A major challenge for CRISPR technology is the delivery of editing tools into the correct cells or tissues.

Expert perspectiveJennifer DoudnaMay 4

Create a free account to see Jennifer Doudna's full intelligence report — every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail